PLSEのチャート
PLSEの企業情報
| symbol | PLSE |
|---|---|
| 会社名 | Pulse Biosciences Inc （パルス・バイオサイエンシズ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 パルス・バイオサイエンス(Pulse Biosciences Inc.)(旧名：Electroblate Inc.)はナノパルス電気信号法（NPES）と呼ばれるプラットフォーム技術を使用する開発段階医療機器会社である。NPESはナノ秒パルス電場を利用して細胞シグナリング及び組織内細胞経路の活性化を誘導する局所的・ドラッグフリー技術である。NPESは各種皮膚科と美容分野での治療法を提供する。同社は心臓アブレーション、肺疾患、バレット食道、甲状腺結節、耳、鼻と咽頭（ENT）乳頭腫等の低侵襲性治療法を提供する。同社はPulseTxシステム（PulseTx）として識別されるNPES治療のシステムを開発する。PulseTxシステムは、可変パルス発生器とその計画された一連の電極を介してNPESパルスを送ります。 PulseTxシステムパルスは電極で組織に直接応用され、細胞と細胞小器官膜に一時的ナノメートル孔を生成する。 パルス・バイオサイエンシズは米国の医療装置メ―カ―。主に「ナノ・パルス・エレクトロ・シグナリング(NPES)」システムを開発する。NPESのパラメ―タを調整することにより、分泌やアポト―シス、壊死を含む細胞反応を誘発することが可能。同社の「パルスTX TM」システムのあるクリニックではNPSEを利用できる。本社はカリフォルニア州。 Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The CellFX® System is the first commercial product to harness the distinctive advantages of the Company's proprietary Nano-Pulse Stimulation™ (NPS™) technology, such as the ability to non-thermally clear cells while sparing non-cellular tissue, to treat a variety of applications for which an optimal solution remains unfulfilled. Nano-Pulse Stimulation technology delivers nano-second pulses of electrical energy. The initial commercial use of the CellFX System is to address a range of dermatologic conditions that share high demand among patients and practitioners for improved dermatologic outcomes. Designed as a multi-application platform, the CellFX System offers customer value with a utilization-based revenue model. |
| 本社所在地 | 3957 Point Eden Way Hayward CA 94545 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | +1 510-906-4600 |
| 設立年月日 | 41760 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | 2016年 |
| 従業員数 | 33人 |
| url | www.pulsebiosciences.com |
| nasdaq_url | https://www.nasdaq.com/symbol/plse |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -33.11900 |
| 終値（lastsale） | 12.7808 |
| 時価総額（marketcap） | 215821010.9568 |
| 時価総額 | 時価総額（百万ドル） 163.45980 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 135.96080 |
| 当期純利益 | 当期純利益（百万ドル） -34.02000 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Pulse Biosciences Inc revenues was not reported. Net loss increased 90% to $17.8M. Higher net loss reflects General and administrative - Balancing v increase from $2.5M to $5.5M (expense) Stock-based Compensation in SGA increase from $2.5M to $5.1M (expense) Research and development - Balancing val increase of 56% to $5.6M (expense). |
PLSEのテクニカル分析
PLSEのニュース
Pulse Biosciences Schedules Fourth Quarter & Full Year 2022 Financial Results Conference Call for March 30, 2023 2023/03/02 21:05:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, announced today it will report financial results for the fourth quarter and full year of 2022 after market close on Thursday, March 30, 2023. Company management will host a corresponding conference call beginning at 1:30pm PT / 4:30pm ET. Investors interested i
Pulse Biosciences Announces Its Novel Nanosecond Pulsed Field Ablation System Will Be Highlighted at the 2023 AF Symposium 2023/02/02 13:00:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary nanosecond pulsed field ablation (nsPFA™) technology for electrophysiology and the treatment of atrial fibrillation, today announced its technology will be highlighted in a poster presentation at the 28th Annual International AF Symposium meeting in Boston February 2–4. The poster highlights the integration of Pulse Bioscience’s nsPFA System with CardioNXT’s iMAP 3-D mapping
Pulse Biosciences Inc. (NASDAQ: PLSE) Could Soon Experience A Sharp Increase In Its Share Price. 2023/01/16 20:00:00 Marketing Sentinel
In the last trading session, 0.12 million shares of the Pulse Biosciences Inc. (NASDAQ:PLSE) were traded, and its beta was 1.10. Most recently the company’s share price was $3.88, and it changed around $0.14 or 3.74% from the last close, which brings the market valuation of the company to $139.21M. PLSE currently trades at a … Pulse Biosciences Inc. (NASDAQ: PLSE) Could Soon Experience A Sharp Increase In Its Share Price. Read More »
Pulse Biosciences CFO Gardiner resigns - SEC filing (NASDAQ:PLSE) 2022/12/06 22:53:46 Seeking Alpha
Pulse Biosciences (PLSE) disclosed in a filing on Tuesday that chief financial officer Sandra Gardiner gave notice of her resignation on November 30.The company said it has began a…
Pulse Biosciences CFO resigns (NASDAQ:PLSE) 2022/12/06 22:51:02 Seeking Alpha
Pulse Biosciences (PLSE) CFO Sandra Gardiner is resigning from the bioelectric medicine company.
Pulse Biosciences CFO Gardiner resigns - SEC filing (NASDAQ:PLSE) 2022/12/06 22:53:46 Seeking Alpha
Pulse Biosciences (PLSE) disclosed in a filing on Tuesday that chief financial officer Sandra Gardiner gave notice of her resignation on November 30.The company said it has began a…
Pulse Biosciences CFO resigns (NASDAQ:PLSE) 2022/12/06 22:51:02 Seeking Alpha
Pulse Biosciences (PLSE) CFO Sandra Gardiner is resigning from the bioelectric medicine company.
Lifshitz Law PLLC Announces Investigations of Natera, Inc. (NASDAQ: NTRA), Butterfly Network, Inc. (NYSE: BFLY), Pulse Biosciences, Inc. (NASDAQ: PLSE), and SunPower Corporation (NASDAQ: SPWR) 2022/11/20 01:07:00 GlobeNewswire
NEW YORK, Nov. 19, 2022 (GLOBE NEWSWIRE) -- Natera, Inc. (NASDAQ: NTRA)
Pulse Biosciences Earnings, Revenue Miss in Q3 By Investing.com 2022/11/11 07:55:00 Investing.com
Pulse Biosciences Earnings, Revenue Miss in Q3
Pulse Biosciences, Inc. (PLSE) Q3 2022 Earnings Call Transcript 2022/11/11 01:02:07 Seeking Alpha
Pulse Biosciences, Inc. (NASDAQ:NASDAQ:PLSE) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Philip Taylor – Investor Relations, Gilmartin Group Kevin…
Pulse Biosciences Schedules Second Quarter 2022 Financial Results Conference Call for August 10, 2022 2022/07/27 20:05:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, announced today it will report financial results for the second quarter of 2022 after market close on Wednesday, August 10, 2022. Company management will host a corresponding conference call beginning at 1:30pm PT. Investors interested in listening to the conference call may do so by dialing 1-877-
Twitter Shares Surge Around 8%, Here''s 66 Biggest Movers From Yesterday 2022/07/14 09:58:12 Benzinga
Gainers Qurate Retail, Inc. (NASDAQ: QRTEB ) shares climbed 71.1% to close at $5.20. Qurate Retail will host a conference call to discuss Q2 results on Friday, August 5th. Liberty TripAdvisor Holdings, Inc. (NASDAQ: LTRPB ) gained 48.9% to close at $14.00 XORTX Therapeutics Inc. (NASDAQ: XRTX ) jumped 47.2% to close at $1.81 after the company announced topline results from Part 1 of the 3 part Pharmacokinetics Bridging Study showed a substantial increase in oral bioavailability of two versions of its proprietary oxypurinol formulation. ironSource Ltd. (NYSE: IS ) rose 47.1% to close at $3.28 after the company announced an all-stock merger agreement with Unity Software at an approximate $4.4 billion. TDH Holdings, Inc. (NASDAQ: PETZ ) jumped 42.2% to close at $2.93. TDH Holdings reported in SEC filing that the company withdraws of registration statement. NuCana plc (NASDAQ: NCNA ) gained 41.4% to close at $1.37. The Regional Court of Dusseldorf recently ruled in favor of the company, stating that Gilead infringed NuCana''s composition of matter claims in European Patent 2955190.
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2022/06/16 20:15:00 Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company commercializing the CellFX® System powered by Nano-Pulse Stimulation™ (NPS™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Company''s 2017 Equity Incentive Plan, but under the terms of the 2017 Equity Incentive Plan. The equity awards were approved and issu
PULSE BIOSCIENCES, INC. FILES (8-K) Disclosing Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits 2022/06/03 20:09:19 InsuranceNewsNet
Pulse Biosciences, Inc. has determined not to renew its directors and officers liability insurance policies this year due to disproportionately high premiums quoted by insurance companies. Instead, Robert W. Duggan, chairman of the Company''s board of directors, and the Company have entered into a letter agreement, dated May 31, 2022 pursuant to which Mr….
Pulse Biosciences, Inc. (NASDAQ:PLSE) Long Term Investor Alert: Investigation of Potential Wrongdoing 2022/06/03 16:45:00 SBWire
An investigation on behalf of current long term investors in Pulse Biosciences, Inc. (NASDAQ:PLSE) shares over possible breaches of fiduciary duty by certain officers and directors was announced. San Diego, CA -- ( SBWIRE ) -- 06/03/2022 -- Certain directors of Pulse Biosciences, Inc. are under investigation concerning potential breaches of fiduciary duties. Investors who are current long term investors in Pulse Biosciences, Inc. (NASDAQ: PLSE) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for investors in NASDAQ: PLSE stocks follows a lawsuit filed against Pulse Biosciences, Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ: PLSE stocks, concerns whether certain Pulse Biosciences, Inc. directors are liable in connection with the allegations made in that lawsuit. The plaintiff alleges that, the Defendants failed to disclose to investors that the IDE study evaluating the use of the CellFX System to treat sebaceous hyperplasia lesions failed to meet its primary endpoints, that, as a result, there was a substantial risk that the FDA would reject Pulse''s 510(k) submission seeking to expand the label for the CellFX System to treat sebaceous hyperplasia lesions, and that, as a result of the foregoing, Defendants'' positive statements about the Company''s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.